Revealing HIV-1 persistence in myeloid cell reservoirs
揭示骨髓细胞储存库中 HIV-1 的持久性
基本信息
- 批准号:10319986
- 负责人:
- 金额:$ 38.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-03-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAffinityAntibodiesBiological AssayBone Marrow TransplantationBostonCD4 Positive T LymphocytesCell surfaceClinicalClinical ResearchDisadvantagedDisease remissionExhibitsFrequenciesGenomeGrowthHIV-1IndividualInfectionInterruptionLightMolecularMolecular CloningMyelogenousMyeloid CellsNaturePatientsPhylogenetic AnalysisPlasmaPlayPropertyProvirusesRecombinantsResearchRoleSamplingShapesSupporting CellTissuesTropismVariantViralViremiaVirusantiretroviral therapycatalystdesignfallsfitnessinsightmacrophageviral rebound
项目摘要
Abstract
Assessing whether myeloid cells support HIV-1 persistence in the face of effective ART represents a significant
technical challenge. As a result, there is as yet, no direct evidence that myeloid cells play any role in viral
persistence in the face of effective ART. As a consequence, research on myeloid cell reservoirs is falling into
obscurity. Infection of macrophages can only be initiated by HIV-1 variants that have the ability to use low levels
of CD4 on the cell surface. Therefore, if a functional myeloid reservoir contributes to viral persistence under
effective ART, we would predict that viremia that rebounds following analytic treatment interruption (ATI), would
contain viral variants that have a high affinity for CD4. We have developed an approach that allows identification
of low frequency macrophage-tropic variants in rebounding viremia post ATI. Through single genome
amplification (SGA), we cloned a large number of viral envelopes from plasma of individuals who underwent ATI.
When these envelopes were used to construct recombinant molecular clones, they conferred the ability to fuse
with, and replicate within primary macrophages. We believe that these results provide definitive evidence
for the existence of a myeloid cell reservoir in infected individuals on suppressive ART and furthermore,
that this reservoir contributes to viral rebound when ART is interrupted.
We hypothesize that the myeloid cell reservoir is stable, permits long term viral persistence under suppressive
ART and fuels viral rebound upon treatment interruption. To pursue this hypothesis, we propose to:
1: Assess the frequency of macrophage-tropic viruses through longitudinal sampling of rebounding
viremia post-ATI.
2: Assess the persistent nature of the myeloid cell reservoir from individuals with prolonged remission
intervals following bone marrow transplant (Boston patients) as well as sampling of rebounding viremia
from individuals who underwent sequential ATI.
3: Evaluate whether macrophage-tropic viruses have a CNS origin and whether they are less fit relative
to T tropic viruses.
This proposal will integrate clinical, virologic and molecular studies to reveal the existence of a myeloid cell
reservoir in individuals on suppressive ART and to shed light on the dynamics of this reservoir. The critical
information gained from this study will provide whether there is rationale for an expanded effort to develop
strategies to target the myeloid cell reservoir and to accelerate the path to a viral cure.
摘要
评估骨髓细胞是否支持HIV-1在有效的ART面前的持久性,
技术挑战。因此,目前还没有直接证据表明骨髓细胞在病毒感染中起任何作用。
因此,对骨髓细胞储库的研究正在陷入困境。
默默无闻巨噬细胞的感染只能由具有使用低水平的能力的HIV-1变体启动
细胞表面的CD 4分子。因此,如果一个功能性的骨髓储库有助于病毒持续存在,
有效的ART,我们预测分析性治疗中断(ATI)后反弹的病毒血症,
含有对CD 4具有高亲和力的病毒变体。我们已经开发出一种允许识别的方法
低频率巨噬细胞嗜性变异体在ATI后反弹病毒血症中的作用通过单个基因组
通过快速扩增(SGA),我们从经历ATI的个体的血浆中克隆了大量的病毒包膜。
当这些包膜用于构建重组分子克隆时,它们赋予了融合的能力,
在原代巨噬细胞内复制。我们相信这些结果提供了明确的证据
在接受抑制性ART的感染个体中存在骨髓细胞储库,此外,
当抗逆转录病毒治疗中断时,这个储存库会导致病毒反弹。
我们假设髓系细胞库是稳定的,在抑制性免疫抑制下允许病毒长期存在。
ART和燃料病毒反弹后,治疗中断。为了实现这一假设,我们建议:
1:通过反弹纵向采样评估嗜巨噬细胞病毒的频率
ATI后病毒血症
2:评估缓解期延长个体骨髓细胞库的持续性
骨髓移植后间隔(波士顿患者)以及反弹病毒血症采样
连续性ATI的患者。
3:评价嗜巨噬细胞病毒是否具有CNS来源,以及它们是否是较不适合的相对
T嗜性病毒。
该提案将整合临床、病毒学和分子研究,以揭示骨髓细胞的存在
在抑制性ART的个人水库,并阐明这个水库的动态。临界
从这项研究中获得的信息将提供是否有理由扩大努力,
针对骨髓细胞库和加速病毒治愈的策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mario Stevenson其他文献
Mario Stevenson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mario Stevenson', 18)}}的其他基金
Irreversible Proviral Silencing in Myeloid Cells
骨髓细胞中不可逆的前病毒沉默
- 批准号:
10705469 - 财政年份:2023
- 资助金额:
$ 38.38万 - 项目类别:
Simple Method for Screening of HIV Drug Resistance in Resource-Limited Settings
在资源有限的环境中筛查 HIV 耐药性的简单方法
- 批准号:
10384759 - 财政年份:2022
- 资助金额:
$ 38.38万 - 项目类别:
Defining a Role for Liver Myeloid Cells in Viral Persistence under ART-SUPPLEMENT 1
ART-补充 1 下定义肝髓细胞在病毒持久性中的作用
- 批准号:
10852118 - 财政年份:2022
- 资助金额:
$ 38.38万 - 项目类别:
Defining a Role for Liver Myeloid Cells in Viral Persistence under ART
定义肝髓细胞在 ART 下病毒持续存在中的作用
- 批准号:
10527635 - 财政年份:2022
- 资助金额:
$ 38.38万 - 项目类别:
Defining a Role for Liver Myeloid Cells in Viral Persistence under ART
定义肝髓细胞在 ART 下病毒持续存在中的作用
- 批准号:
10654037 - 财政年份:2022
- 资助金额:
$ 38.38万 - 项目类别:
Revealing HIV-1 persistence in myeloid cell reservoirs
揭示骨髓细胞储存库中 HIV-1 的持久性
- 批准号:
10709063 - 财政年份:2018
- 资助金额:
$ 38.38万 - 项目类别:
Reservoir activity and recrudescent virus composition in HIV and SIV rebound
HIV 和 SIV 反弹中的病毒库活性和复发病毒组成
- 批准号:
10205971 - 财政年份:2017
- 资助金额:
$ 38.38万 - 项目类别:
Reservoir activity and recrudescent virus composition in HIV and SIV rebound
HIV 和 SIV 反弹中的病毒库活性和复发病毒组成
- 批准号:
9332149 - 财政年份:2017
- 资助金额:
$ 38.38万 - 项目类别:
HIV-a Persistence in Myeloid Cell Reservoirs
HIV-a 在骨髓细胞库中的持续存在
- 批准号:
9204094 - 财政年份:2016
- 资助金额:
$ 38.38万 - 项目类别:
Preclinical Development of HIV-1 Vif Antagonists - Project 2
HIV-1 Vif 拮抗剂的临床前开发 - 项目 2
- 批准号:
8723304 - 财政年份:2014
- 资助金额:
$ 38.38万 - 项目类别:
相似海外基金
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
- 批准号:
10549640 - 财政年份:2023
- 资助金额:
$ 38.38万 - 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
- 批准号:
2750554 - 财政年份:2021
- 资助金额:
$ 38.38万 - 项目类别:
Studentship
Affinity Biosensors for COVID-19 Antibodies
适用于 COVID-19 抗体的亲和生物传感器
- 批准号:
61319 - 财政年份:2020
- 资助金额:
$ 38.38万 - 项目类别:
Feasibility Studies
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10013588 - 财政年份:2020
- 资助金额:
$ 38.38万 - 项目类别:
Affinity maturation and property changes of single-domain antibodies through repeated immunizations.
通过重复免疫,单域抗体的亲和力成熟和性质变化。
- 批准号:
20K07009 - 财政年份:2020
- 资助金额:
$ 38.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
基于快速结构的软件可增强抗体亲和力和高通量筛选的可开发性:旨在实现抗体的全面计算机设计
- 批准号:
10603473 - 财政年份:2020
- 资助金额:
$ 38.38万 - 项目类别:
IN SILICO DESIGN OF HIGH-AFFINITY RECOMBINANT ANTIBODIES
高亲和力重组抗体的计算机模拟设计
- 批准号:
2342674 - 财政年份:2020
- 资助金额:
$ 38.38万 - 项目类别:
Studentship
Strategies for generating high affinity antibodies against Gram negative bacteria
产生针对革兰氏阴性菌的高亲和力抗体的策略
- 批准号:
10117194 - 财政年份:2020
- 资助金额:
$ 38.38万 - 项目类别:
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10115604 - 财政年份:2020
- 资助金额:
$ 38.38万 - 项目类别:
Interdisciplinary protein engineering approach to design high affinity antibodies for flaviviruses
跨学科蛋白质工程方法设计黄病毒高亲和力抗体
- 批准号:
10294224 - 财政年份:2018
- 资助金额:
$ 38.38万 - 项目类别: